Immunocore Holdings plc Marketable Securities, Unrealized Gain (Loss)
Immunocore Holdings plc (IMCR) reported Marketable Securities, Unrealized Gain (Loss) of $4.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was $3.07M, a 34.56% decline year-over-year.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was $1.78M, a 67.53% decline year-over-year.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $4.50M, a 324.11% increase year-over-year.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $5.06M, a 43.14% decline year-over-year.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for fiscal 2025 was $19.73M, a 35.34% increase from fiscal 2024.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for fiscal 2024 was $14.58M.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for fiscal 2023 was $0.00.
- Immunocore Holdings plc marketable securities, unrealized gain (loss) for fiscal 2022 was $0.00.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.85M 10-Q · filed 2026-08-06 | $9.35M derived: sum of 3 quarters · filed 2026-08-06 | $14.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.78M 10-Q · filed 2026-05-06 | $6.28M derived: sum of 2 quarters · filed 2026-05-06 | $11.34M derived: sum of 3 quarters · filed 2026-05-06 | $16.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.57M derived: sum of 2 quarters · filed 2026-02-25 | $14.26M derived: sum of 3 quarters · filed 2026-08-06 | $19.73M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.76M derived: sum of 2 quarters · filed 2026-08-06 | $15.22M 10-Q · filed 2025-11-06 | $16.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.16M 10-Q · filed 2026-08-06 | $11.22M derived: sum of 3 quarters · filed 2026-08-06 | $20.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.47M 10-Q · filed 2026-05-06 | $6.53M derived: sum of 2 quarters · filed 2026-05-06 | $15.43M derived: sum of 3 quarters · filed 2026-05-06 | $20.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.96M derived: sum of 2 quarters · filed 2026-02-25 | $14.58M derived: sum of 3 quarters · filed 2026-02-25 | $14.58M 10-K · filed 2026-02-25 |
| 2024-09-30 | $8.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $13.52M derived: sum of 2 quarters · filed 2025-11-06 | $13.52M 10-Q · filed 2025-11-06 | $13.52M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $4.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.61M 10-Q · filed 2025-08-07 | $4.61M derived: sum of 3 quarters · filed 2026-02-25 | $4.61M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |